Management of the Blind Eye and Options for Cosmesis

Authors

  • Vivian T. Yin, MD, MPH Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia

Abstract

As ophthalmologists, our ultimate goal in the treatment of patients with eye conditions is the preservation of vision and the eye. However, there are conditions necessitating the removal of an eye for pain control; control of infection source; treatment of malignancy; severe trauma; perforated corneal ulcer; or cosmesis. Over the years, there has been a shift in both surgical techniques and choice of implants, all with the goal to improve cosmesis outcome and decrease implant exposure and extrusion. However, there remains a wide range of approaches due to the variety of patient and disease factors. We present here an overview for how to think through the different aspects of eye removal and the subsequent cosmetic rehabilitation.

Author Biography

Vivian T. Yin, MD, MPH, Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia

Dr. Vivian T. Yin is a clinical associate professor at the University of British Columbia specialized in ophthalmic plastic and reconstructive surgery. She worked at Memorial Sloan Kettering Cancer Center in New York and returned to Vancouver in Nov 2019. She focuses on the treatment of periocular and orbital cancer, with the use of genetic-based targeted therapy and surgical innovations as her research interest, and speaks internationally on these topics. After completing her medical degree and ophthalmology residency at the University of Toronto, she pursued a prestigious 2-year fellowship training in Ophthalmic Plastics and Reconstructive Surgery at the University of Texas M.D. Anderson Cancer Center in Houston, Texas. Dr. Yin also practices in global health with a Master in Public Health from the Johns Hopkins Bloomberg School of Public Health. She generously donates her spare time to work towards eliminating preventable blindness. She has traveled to Bangladesh, the Philippines, Nepal, Tunisia and India to teach and provide surgical care for those in need. She is the current chair of the Canadian Association for Public Health and Global Ophthalmology and the COS representative to the International Council of Ophthalmology. She was chair and member of the board of director for Seva Canada for 6 years.

References

Sigurdsson H, Thorisdottir S, Bjornsson JK. Enucleation and evisceration in Iceland 1964-1992. Study in a defined population. Acta Ophthalmol Scand. 1998;103-107.

Shah RD, Singa RM, Aakalu VK, et al. Evisceration and enucleation: A national survey of practice patterns in the United States. Ophthalmic Surg Lasers Imaging. 2012;43(5):425-430.

Koh V, Chiam N, Sundar G. Survey of common practices among oculofacial surgeons in the Asian-Pacific region: Evisceration, enucleation and management of anophthalmic sockets. Orbit. 2014;33(6):477.

Eagle RC Jr, Grossniklaus HE, Syed N, et al. Inadvertent evisceration of eyes containing uveal melanoma. Arch Ophthalmol. 2009;127(2):141-145.

Schefler AC, Abramson DH. Should evisceration ever be done in a blind, painful eye? Arch Ophthalmol. 2009;127(2):211-212.

Shams PN, Bohman E, Baker MS, et al. Chronic anophthalmic socket pain treated by implant removal and dermis fat graft. Br J Ophthalmol. 2015;99(12):1692-1696.

Shah-Desai SD, Tyers AG, Manners RM. Painful blind eye: efficacy of enucleation and evisceration in resolving ocular pain. Br J Ophthalmol. 2000;84(4):437-438.

Hogeboom CSE, Mourits DL, Ket JCF, et al. Persistent socket pain post enucleation and post evisceration: A systemic review. Acta Ophthalmol. 2018 Nov;96(7):661-672.

Kilmartin DJ, Dick AD, Forrester JV. Prospective surveillance of sympathetic ophthalmia in the UK and Republic of Ireland. Br J Ophthalmol. 2000 March;84:259-263.

Kilmartin DJ, Dick AD, Forrester JV. Sympathetic ophthalmia risk following vitrectomy: Should we counsel patients? Br J Ophthalmol. 2000;84:448-449.

Jordan DR, Dutton JJ. The rupture blobe, sympathetic ophthalmia, and the 14-day rule. Ophthalmic Plast Reconstr Surg. 2022;38(4):315-324.

Brackup AB, Carter KD, Nerad JA, et al. Long-term follow-up of severely injured eyes following globe rupture. Ophthalmic Plastic Reconstr Surg. 1991;7(3):194-197.

Tripathy D, Rath S. Evisceration with primary orbital implant in fulminant endophthalmitis/panophthalmitis. Orbit. 2015;34(5):279-283.

Tianthong W, Aryasit O. Outcomes of evisceration or enucleation by resident trainees in patients with recalcitrant endophthalmitis or panophthalmisit. Medicine. 2022;101:30.

Hui JI. Outcomes of orbital implants after evisceration and enucleation in patients with enophthalmitis. Curr Opinion Ophthalmol. 2010;21:375-379.

Lin CW, Liao SL. Long-term complications of different porous orbital implants: A 21-year review. Br J Ophthalmol. 2017;101(5):681-685.

Su GW, Yen MT. Current trends in managing the anophthalmic socket after primary enucleation and evisceration. Ophthalmic Plast Reconstr Surg. 2004;20(4):274-280.

Shome D, Honavar SG, Raizada K, et al. Implant and prosthesis movement after enucleation: A randomized controlled trial. Ophthalmol. 2010;117:1638-1644.

Custer PL, Maamari RN, Huecker JB, et al. Anophthalmic ptosis and the effect of enucleation on upper eyelid function. Ophthalmic Plast Reconstr Surg 2021;37(3S):S80-S84.

Downloads

Published

2023-10-23

How to Cite

1.
Yin VT. Management of the Blind Eye and Options for Cosmesis. Can Eye Care Today [Internet]. 2023 Oct. 23 [cited 2024 Mar. 3];2(3):5–9. Available from: https://canadianeyecaretoday.com/article/view/2-3-yin

Issue

Section

Articles